Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

CLINDAMYCIN

All products: not a benefit

Other products in the same Health Canada class (D10AF) — coverage varies; not interchangeable

  • Benzoyl peroxide + clindamycin (Clindoxyl): general benefit
  • Adapalene + benzoyl peroxide + clindamycin (Cabtreo): limited Use 724

Taro-Clindamycin · DIN 02266938 · 1% · Top Sol

Off-Formulary Interchangeable, not an ODB benefitMarketed · checked 2026-09-02
StatusOff-Formulary Interchangeable, not an ODB benefit
Write on scriptnot a benefit; no Exceptional Access criteria on record; see alternatives
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Taro-Clindamycin · DIN 02266938 Manufacturer: Taro Pharmaceuticals Inc.; listing date 2017-03-28 Health Canada: Marketed since 2005-10-03 · brand TARO-CLINDAMYCIN · ATC D10AF01 CLINDAMYCIN · form Solution · route Topical · ingredients CLINDAMYCIN (CLINDAMYCIN PHOSPHATE) 1 %/W/V · company Taro pharmaceuticals inc · schedule Prescription
Check this DIN again · Health Canada product record

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75233 · Verify on the e-Formulary ↗ (DIN 02266938)

Source record
DIN 02266938: Taro-Clindamycin Raw flags: notABenefit=Y, sec3=Y, sec3b=Y Item: 840404017; group id 809; item number 1987; lccId None; manufacturer id TAR Source form: Top Sol; strength: 1% Recorded listing: Off-Formulary Interchangeable, not an ODB benefit Source prices (unrounded): $0.5072; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02266938 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=75233
Interchangeable products
Dalacin T 1% · DIN 00582301 · not recorded
Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02266938
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (84:04:04 Antibiotics) and how they are covered

Matched class: 84:04:04 Antibiotics

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE, FUSIDIC ACID, MUPIROCIN CALCIUM, SODIUM FUSIDATE Some products covered without a code (check the product listing): MUPIROCIN 84:04:04 Antibiotics

CLINDAMYCIN PHOSPHATE & BENZOYL PEROXIDE

· 4 products · General benefit · strengths: 1% & 5% · Gel, Top Gel

CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE

· 1 products · Limited Use, codes 724 · strengths: 1.2% w/w & 0.15% w/w & 3.1% w/w · Top Gel Pump

FUSIDIC ACID

· 2 products · General benefit · strengths: 2% · Cr

MUPIROCIN

· 2 products · Listed, not a benefit (1), General benefit (1) · strengths: 2% · Oint

MUPIROCIN CALCIUM

· 1 products · General benefit · strengths: 2% w/w · Cr

SODIUM FUSIDATE

· 2 products · General benefit · strengths: 2% · Oint Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 84:04:04
Full class listing Related classes: 84:04:08 Fungicides, 84:04:12 Parasiticides, 84:04:16 Other Anti-Infectives Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: acne
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. No displayed matched alternative is a general benefit. CLINDAMYCIN PHOSPHATE & ADAPALENE & BENZOYL PEROXIDE · Limited Use, codes 724 1 INDICATIONS CABTREO (clindamycin phosphate, adapalene and benzoyl peroxide) is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. PM: https://pdf.hres.ca/dpd_pm/00076715.PDF; date AUG 14, 2024; DIN 02550423; fetched 2026-09-10 Product monograph TAZAROTENE · Limited Use, codes 636 1 INDICATIONS ARAZLO™ (tazarotene lotion), is indicated for: • For the topical treatment of acne vulgaris in patients 10 years of age and older. 1.1 Pediatrics Pediatrics (≥ 10 years of age) The safety and efficacy of ARAZLO in pediatric patients (10 years of age and older) has been established. PM: https://pdf.hres.ca/dpd_pm/00082613.PDF; date NOV 28, 2025; DIN 02517868; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE Taro-Clindamycin 1% (clindamycin phosphate) is indicated for the treatment of acne vulgaris. To reduce the development of drug-resistant bacteria and maintain the effectiveness of DALACIN T and other antibacterial drugs, DALACIN T should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Geriatrics (> 65 years of age): Clinical studies of clindamycin did not include sufficient numbers of patients age 65 and over to determine whether they respond differently from younger patients. Pediatrics Safety and effectiveness in pediatric patients under the age of 12 have not been established. https://pdf.hres.ca/dpd_pm/00058691.PDF PM date: not printed or not captured Source product: TARO-CLINDAMYCIN; DIN 02266938; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Taro-Clindamycin · DIN 02266938 Shortage status: To be discontinued; reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02266938

Check this DIN again

Other review policies

For Taro-Clindamycin: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026